Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
Abstract Aims Epidemiological heart failure (HF) data in the era of natriuretic peptides and echocardiography are scarce. The primary aim of this study is to evaluate the HF prevalence in the general population. We will also investigate natriuretic peptide cut‐off for diagnosis of HF. Finally, we wi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-10-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.12496 |
| _version_ | 1819035449712181248 |
|---|---|
| author | Mitja Lainscak Daniel Omersa Natasa Sedlar Stefan D. Anker Jerneja Farkas |
| author_facet | Mitja Lainscak Daniel Omersa Natasa Sedlar Stefan D. Anker Jerneja Farkas |
| author_sort | Mitja Lainscak |
| collection | DOAJ |
| description | Abstract Aims Epidemiological heart failure (HF) data in the era of natriuretic peptides and echocardiography are scarce. The primary aim of this study is to evaluate the HF prevalence in the general population. We will also investigate natriuretic peptide cut‐off for diagnosis of HF. Finally, we will be able to identify left ventricular function phenotypes and study relations between cardiac function, clinical presentation, and health‐related quality of life. Methods and results Screening Of adult urBan pOpulation To diAgnose Heart Failure (SOBOTA‐HF) is a cross‐sectional prevalence study in a representative sample of Murska Sobota residents aged 55 years or more. Individuals will be invited to attend screening visit with point‐of‐care N‐terminal pro‐b‐type natriuretic peptide (NT‐proBNP) testing. All subjects with NT‐proBNP ≥ 125 pg/mL will be invited for a diagnostic visit that will include history and physical examination, electrocardiogram, echocardiography, blood and urine sampling, ankle brachial index, pulmonary function tests, body composition measurement, physical performance tests, and questionnaires. To validate the screening procedure, a control group (NT‐proBNP < 125 pg/mL) will undergo the same diagnostic evaluation. An external centre will validate echocardiography results, and the HF diagnosis will be adjudicated within an international HF expert panel. Overall and age‐specific HF prevalence will be calculated in individuals ≥ 55 years and extrapolated to the whole population. Conclusions The SOBOTA‐HF study will test the latest HF guideline diagnostic criteria in the general population sample. Next to HF prevalence, it will provide insight into left ventricular function and general patient phenotype; we will also extend current understanding of natriuretic peptides for HF screening. |
| first_indexed | 2024-12-21T07:49:49Z |
| format | Article |
| id | doaj.art-3b2edc9226814e2881be08f3000a1294 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-12-21T07:49:49Z |
| publishDate | 2019-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-3b2edc9226814e2881be08f3000a12942022-12-21T19:11:07ZengWileyESC Heart Failure2055-58222019-10-01651077108410.1002/ehf2.12496Heart failure prevalence in the general population: SOBOTA‐HF study rationale and designMitja Lainscak0Daniel Omersa1Natasa Sedlar2Stefan D. Anker3Jerneja Farkas4General Hospital Murska Sobota Ulica dr. Vrbnjaka 6, Rakican SI‐9000 Murska Sobota SloveniaGeneral Hospital Murska Sobota Ulica dr. Vrbnjaka 6, Rakican SI‐9000 Murska Sobota SloveniaNational Institute of Public Health Ljubljana SloveniaDepartment of Cardiology (CVK) Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin Berlin GermanyGeneral Hospital Murska Sobota Ulica dr. Vrbnjaka 6, Rakican SI‐9000 Murska Sobota SloveniaAbstract Aims Epidemiological heart failure (HF) data in the era of natriuretic peptides and echocardiography are scarce. The primary aim of this study is to evaluate the HF prevalence in the general population. We will also investigate natriuretic peptide cut‐off for diagnosis of HF. Finally, we will be able to identify left ventricular function phenotypes and study relations between cardiac function, clinical presentation, and health‐related quality of life. Methods and results Screening Of adult urBan pOpulation To diAgnose Heart Failure (SOBOTA‐HF) is a cross‐sectional prevalence study in a representative sample of Murska Sobota residents aged 55 years or more. Individuals will be invited to attend screening visit with point‐of‐care N‐terminal pro‐b‐type natriuretic peptide (NT‐proBNP) testing. All subjects with NT‐proBNP ≥ 125 pg/mL will be invited for a diagnostic visit that will include history and physical examination, electrocardiogram, echocardiography, blood and urine sampling, ankle brachial index, pulmonary function tests, body composition measurement, physical performance tests, and questionnaires. To validate the screening procedure, a control group (NT‐proBNP < 125 pg/mL) will undergo the same diagnostic evaluation. An external centre will validate echocardiography results, and the HF diagnosis will be adjudicated within an international HF expert panel. Overall and age‐specific HF prevalence will be calculated in individuals ≥ 55 years and extrapolated to the whole population. Conclusions The SOBOTA‐HF study will test the latest HF guideline diagnostic criteria in the general population sample. Next to HF prevalence, it will provide insight into left ventricular function and general patient phenotype; we will also extend current understanding of natriuretic peptides for HF screening.https://doi.org/10.1002/ehf2.12496Heart failurePrevalenceEpidemiologyRationale and DesignNatriuretic peptide |
| spellingShingle | Mitja Lainscak Daniel Omersa Natasa Sedlar Stefan D. Anker Jerneja Farkas Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design ESC Heart Failure Heart failure Prevalence Epidemiology Rationale and Design Natriuretic peptide |
| title | Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design |
| title_full | Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design |
| title_fullStr | Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design |
| title_full_unstemmed | Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design |
| title_short | Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design |
| title_sort | heart failure prevalence in the general population sobota hf study rationale and design |
| topic | Heart failure Prevalence Epidemiology Rationale and Design Natriuretic peptide |
| url | https://doi.org/10.1002/ehf2.12496 |
| work_keys_str_mv | AT mitjalainscak heartfailureprevalenceinthegeneralpopulationsobotahfstudyrationaleanddesign AT danielomersa heartfailureprevalenceinthegeneralpopulationsobotahfstudyrationaleanddesign AT natasasedlar heartfailureprevalenceinthegeneralpopulationsobotahfstudyrationaleanddesign AT stefandanker heartfailureprevalenceinthegeneralpopulationsobotahfstudyrationaleanddesign AT jernejafarkas heartfailureprevalenceinthegeneralpopulationsobotahfstudyrationaleanddesign |